Show simple item record

dc.contributor.authorNewman, AM
dc.contributor.authorZaka, M
dc.contributor.authorZhou, P
dc.contributor.authorBlain, AE
dc.contributor.authorErhorn, A
dc.contributor.authorBarnard, A
dc.contributor.authorCrossland, RE
dc.contributor.authorWilkinson, S
dc.contributor.authorEnshaei, A
dc.contributor.authorDe Zordi, J
dc.contributor.authorHarding, F
dc.contributor.authorTaj, M
dc.contributor.authorWood, KM
dc.contributor.authorTelevantou, D
dc.contributor.authorTurner, SD
dc.contributor.authorBurke, GAA
dc.contributor.authorHarrison, CJ
dc.contributor.authorBomken, S
dc.contributor.authorBacon, CM
dc.contributor.authorRand, V
dc.date.accessioned2022-02-28T17:00:37Z
dc.date.available2022-02-28T17:00:37Z
dc.date.issued2020-03
dc.date.submitted2021-03-02
dc.identifier.issn0887-6924
dc.identifier.others41375-021-01444-6
dc.identifier.other1444
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/334510
dc.descriptionFunder: RCUK | Medical Research Council (MRC); doi: https://doi.org/10.13039/501100000265
dc.descriptionFunder: Good Will Cause
dc.descriptionFunder: MRC/EPSRC Newcastle Pathology Node
dc.descriptionFunder: Newcastle upon Tyne Hospitals NHS Foundation Trust (Newcastle upon Tyne Hospitals NHS Trust); doi: https://doi.org/10.13039/501100003776
dc.descriptionFunder: Blood Cancer UK - Senior Bennett Fellowship #12005 North East Promenaders Against Cancer (NEPAC) The Little Princess Trust JGW Patterson Foundation
dc.description.abstractAbstract: Children with B-cell non-Hodgkin lymphoma (B-NHL) have an excellent chance of survival, however, current clinical risk stratification places as many as half of patients in a high-risk group receiving very intensive chemo-immunotherapy. TP53 alterations are associated with adverse outcome in many malignancies; however, whilst common in paediatric B-NHL, their utility as a risk classifier is unknown. We evaluated the clinical significance of TP53 abnormalities (mutations, deletion and/or copy number neutral loss of heterozygosity) in a large UK paediatric B-NHL cohort and determined their impact on survival. TP53 abnormalities were present in 54.7% of cases and were independently associated with a significantly inferior survival compared to those without a TP53 abnormality (PFS 70.0% vs 100%, p < 0.001, OS 78.0% vs 100%, p = 0.002). Moreover, amongst patients clinically defined as high-risk (stage III with high LDH or stage IV), those without a TP53 abnormality have superior survival compared to those with TP53 abnormalities (PFS 100% vs 55.6%, p = 0.005, OS 100% vs 66.7%, p = 0.019). Biallelic TP53 abnormalities were either maintained from the presentation or acquired at progression in all paired diagnosis/progression Burkitt lymphoma cases. TP53 abnormalities thus define clinical risk groups within paediatric B-NHL and offer a novel molecular risk stratifier, allowing more personalised treatment protocols.
dc.languageen
dc.publisherNature Publishing Group UK
dc.subjectArticle
dc.subject/631/67/69
dc.subject/692/699/1541/1990/291/1621/1915
dc.subject/45/61
dc.subject/45/22
dc.subject/45/23
dc.subject/45/77
dc.subjectarticle
dc.titleGenomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma
dc.typeArticle
dc.date.updated2022-02-28T17:00:37Z
prism.endingPage789
prism.issueIdentifier3
prism.publicationNameLeukemia
prism.startingPage781
prism.volume36
dc.identifier.doi10.17863/CAM.81928
dcterms.dateAccepted2021-09-29
rioxxterms.versionofrecord10.1038/s41375-021-01444-6
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidBlain, AE [0000-0001-8045-822X]
dc.contributor.orcidTurner, SD [0000-0002-8439-4507]
dc.contributor.orcidBurke, GAA [0000-0003-2671-9972]
dc.contributor.orcidRand, V [0000-0002-2198-8949]
dc.identifier.eissn1476-5551


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record